International Cholangiocarcinoma Research Network (ICRN)
The ICRN is a global collaboration of research groups from renowned institutions who are working in concert to improve knowledge about cholangiocarcinoma etiology, prevention, early detection, treatment, and prognosis. The network is comprised of highly talented individuals from a spectrum of disciplines, perspectives, and research methods who share a passion to make significant scientific advances to improve outcomes for patients with cholangiocarcinoma.
The goal of ICRN is to accelerate the clinical translation of scientific discoveries to impact the lives of patients with cholangiocarcinoma.
- Improve the prognosis and quality of life for patients with cholangiocarcinoma, and ultimately cure this disease
- Advance the pace of cholangiocarcinoma research
- Provide a platform for investigators to work collaboratively on cholangiocarcinoma-related projects
- Foster promising clinical and translational studies relevant to cholangiocarcinoma
- Catalyze and expand patient access to clinical trials for promising new treatments
- Enable scientists to rapidly share discoveries and accelerate the drug development landscape
- Provide scientifically valid consensus opinions on the diagnosis and treatment of cholangiocarcinoma
If your industry or biotech company or organization is interested in partnering with the ICRN for the purposes of cholangiocarcinoma research and potential collaboration, please fill out the ICRN Industry Request for Engagement form.
ICRN Members Map
ICRN Executive Committee
Milind Javle, MD
UT MD Anderson Cancer Center
Mitesh Borad, MD
Mayo Clinic, Arizona
Laura Goff, MD
Biliary Cancer Alterations Predict Therapy Choice (BATCH)
Vanderbilt Ingram Cancer Center
Lipika Goyal, MD
Biorepository and Genomic Research Workgroup Chair
Massachusetts General Hospital/Harvard University